Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07081503 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Phase 1 Study of ADX-626 in Healthy Participants

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗

Record History

  1. Completion pushed from Jan 22, 2027 to Jun 30, 2027v7
  2. 3 versions Re-verified since Feb 27, 2026, no change to tracked fieldsv4-v6
  3. Study sites: 2 to 1v3
  4. Trial status: Not Yet Recruiting to Recruiting Study sites: 1 to 2 · Start date changed from estimate of Jul 14, 2025 to Aug 12, 2025v2 Show 2 more changesShow less
    • Study sites: 1 to 2
    • Start date changed from estimate of Jul 14, 2025 to Aug 12, 2025
  5. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This first-in-human study will evaluate the safety and tolerability of ADX-626 in healthy participants. The study will also look at how ADX-626 interacts with the human body (the pharmacokinetics and pharmacodynamics of ADX-626).
Trial Details
NCT Number NCT07081503
Lead Sponsor ADARx Pharmaceuticals, Inc.
Conditions Healthy Adult Participants
Enrollment 44 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov